The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 61)
Improved Biomarkers & Clinical Outcome Measures, 2015
Over the past 14 years, we have utilized sophisticated commercial eye movement monitoring equipment to collect data from over 3300 participants. Our work aims to identify abnormal eye movement features in people with Parkinson's disease (PD) that are not present in those with other movement disorders or in healthy individuals. Our preliminary studies in those wi...
Improved Biomarkers and Clinical Outcome Measures, 2015
White blood cells from people with Parkinson's disease (PD) patients appear to differ from those of control individuals in that there are differences in the set of genes that are turned on in PD lymphocytes (small white blood cells) compared to controls. In our preliminary study of a subpopulation of white blood cells from PD patients, we found unexpected and dramatically altered f...
Researchers: Paul Robert Fisher, PhD, Msc, Bsc
Biomarker Development, 2015
Our project aims to develop a brain imaging agent for alpha-synuclein, a key protein involved in Parkinson's disease (PD) pathology. Such an agent will help (i) diagnose PD earlier, (ii) track pathology over time and (iii) monitor the efficacy of therapeutics reducing alpha-synuclein aggregates. The AC Immune team identified promising compounds that will be refined to target such a...
Access to Data and Biospecimens, 2015
The dysfunction of the systems responsible for the clearance of the protein alpha-synuclein plays a major role in Parkinson's disease (PD). The lysosome is an important sub-cellular compartment for alpha-synuclein disposal. Among the many lysosomal enzymes responsible for this degradation, major attention has been given to glucocerebrosidase (GCase). Several repo...
Therapeutic Pipeline Program, 2015
The abnormal aggregation of a protein known as alpha-synuclein appears to play a critical role in Parkinson's disease. This project will explore a new type of biomolecule, known as an aptamer, as a potential inhibitor of alpha-synuclein aggregation. We aim to discover an aptamer with anti-aggregation properties and then test its ability to thwart alpha-synuclein ag...